Advanced Solid TumorsPhase 2NCT03797326
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
A Phase 2 study testing Pembrolizumab and Lenvatinib in people with Advanced Solid Tumors and Triple Negative Breast Cancer, run by Merck Sharp & Dohme LLC at 88 sites in 17 countries.
Trial summary
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer
- What is being tested?
- Pembrolizumab and Lenvatinib
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 611 participants
- Where
- 88 sitesin 17 countries
- Study dates
- 12 Feb 2019to 28 Oct 2024
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Has a histologically or cytologically-documented, advanced (metastatic and/or unresectable) solid tumor that is incurable and for which prior standard systemic therapy has failed in one of the following cohorts: TNBC, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, GBM, BTC (intrahepatic, extrahepatic cholangiocarcinoma and gall bladder cancer; excludes Ampulla of Vater), Pancreatic Cancer
- Must have progressed on or since the last treatment
- Has measurable disease per RECIST 1.1 (RANO for the GBM cohort) as assessed by the local site investigator/radiology and confirmed by BICR
- Has provided a PD-L1 evaluable archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
- Male participants agree to use approved contraception during the treatment period for at least 7 days after the last dose of lenvatinib, or refrain from heterosexual intercourse during this period
- Female participants are not pregnant or breastfeeding, and are not a woman of childbearing potential (WOCBP), OR are a WOCBP that agrees to use contraception during the treatment period (or 14 days prior to the initiation of study treatment for oral contraception) and for at least 120 days post pembrolizumab, or 30 days post lenvatinib, whichever occurs last
Show all 31Show fewer
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 3 days of study treatment initiation
- Has adequate organ function
- For Triple Negative Breast Cancer Participants:
- Has received one or 2 prior lines of therapy
- Has Lactate Dehydrogenase (LDH) <2.0 x Upper Limit of Normal (ULN)
- Has locally determined results for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 tumor analyses
- For Ovarian Cancer Participants:
- Has primary ovarian cancer and has received 3 prior lines of therapy.
- For Gastric Cancer Participants:
- Has received 2 prior lines of therapy. Note: Gastric cancer will include participants with both gastric and gastroesophageal junction (GEJ) adenocarcinoma. Participants with squamous cell carcinoma histology are not eligible
- For Colorectal Cancer Participants:
- Has received 2 prior lines of therapy
- For GBM Participants:
- Has failed initial systemic therapy for newly diagnosed GBM
- Have the following time periods elapsed before the projected start of scheduled study treatment: 1) at least 3 weeks from prior surgical resection, 2) at least 1 week from stereotactic biopsy, 3) at least 6 months from completion of prior radiotherapy, 4) at least 4 weeks (or 5 half-lives, whichever is shorter) from any investigational agent, 5) at least 4 weeks from cytotoxic therapy, 6) at least 6 weeks from antibodies, 7) at least 4 weeks (or 5 half-lives, whichever is shorter) from other antitumor therapies and 1 week for cancer vaccines
- Be neurologically stable (e.g. without a progression of neurologic symptoms or requiring escalating doses of systemic steroid therapy within last 2 weeks) and clinically stable
- Has histologically confirmed World Health Organization (WHO) Grade IV GBM
- Has locally determined result for O^6-methylguanine-DNA methyltransferase (MGMT) analysis
- For Biliary Tract Cancer Participants:
- Has received 1 prior line of therapy
- Child-Pugh Score, Class A: well-compensated disease. Child-Pugh Score of 5-6
- For Pancreatic Cancer Participants:
- Has pathologically (histologically or cytologically) confirmed pancreatic ductal adenocarcinoma that is metastatic at enrollment
- Has received one or 2 prior lines of therapy
- Has received prior therapy with at least 1 (platinum-containing regimen or gemcitabine-containing regimen) but no more than 2 prior systemic therapies for unresectable or metastatic pancreatic cancer
Who cannot join
- Has gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib
- Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment (applies to all cohorts except the ovarian cancer cohort)
- Has radiographic evidence of encasement or invasion of a major blood vessel or of intratumoral cavitation. Participants with portal vein invasion (Vp4), inferior vena cava, or cardiac involvement based on imaging in the BTC cohort are not eligible for enrollment
- Has clinical significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study treatment
- Has significant cardiovascular impairment within 12 months of the first dose of study treatment, such as history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident (CVA), or cardiac arrhythmia associated with hemodynamic instability
- Has a history of arterial thromboembolism within 12 months of start of study treatment
Show all 37Show fewer
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Has a serious nonhealing wound, ulcer or bone fracture
- Has had major surgery within 3 weeks prior to first dose of study interventions
- Has biologic response modifiers therapy (e.g. granulocyte colony-stimulating factor) within 4 weeks before study entry
- Has preexisting ≥Grade 3 gastrointestinal (GI) or non-gastrointestinal fistula
- Has received prior therapy with lenvatinib, an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9 [CD137])
- Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study treatment start
- If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
- Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease
- Has received a live vaccine within 30 days prior to the first dose of study treatment
- Has known intolerance to lenvatinib (and/or any of the excipients)
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
- Has known active CNS metastases and/or carcinomatous meningitis
- Has tumors involving the brain stem
- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
- Has an active infection requiring systemic therapy
- Has a known history of human immunodeficiency virus (HIV) infection
- Has a known history of hepatitis B or known active hepatitis C virus infection
- Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
- Has had an allogenic tissue/solid organ transplant (large organ transplants, stem-cell transplant requiring chronic immunosuppressant therapy necessary to prevent graft rejection)
- For GBM Participants:
- Has carcinomatous meningitis
- Has recurrent tumor greater than 6 cm in maximum diameter
- Has tumor primarily localized to the brainstem or spinal cord
- Has presence of multifocal tumor, diffuse leptomeningeal or extracranial disease
- Has evidence of intratumoral or peritumoral hemorrhage on baseline magnetic resonance imaging (MRI) scan other than those that are grade ≤ 1 and either post-operative or stable on at least 2 consecutive MRI scans
- Has received Optune® TTFields within 2 weeks of study intervention
Trial locations and contacts
88 sites in 17 countries.
88 sites in 17 countries
United States14 sites
Lehigh Valley Hospital- Cedar Crest ( Site 0047)
Allentown, Pennsylvania, 18103
University of Colorado, Anschutz Cancer Pavilion ( Site 0007)
Aurora, Colorado, 80045
Mary Crowley Cancer Research Centers - Medical City Hospital ( Site 0049)
Dallas, Texas, 75230
City of Hope ( Site 0002)
Duarte, California, 91010
Sanford Fargo Medical Center ( Site 0059)
Fargo, North Dakota, 58102
West Cancer Center - East Campus ( Site 0018)
Germantown, Tennessee, 38138
Cedars Sinai Medical Center ( Site 0003)
Los Angeles, California, 90048
University of Wisconsin Carbone Cancer Center ( Site 0017)
Madison, Wisconsin, 53792-0001
Rutgers Cancer Institute of New Jersey ( Site 0009)
New Brunswick, New Jersey, 08901
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0023)
New York, New York, 10016
University of Florida-Health Cancer Center-Orlando ( Site 0015)
Orlando, Florida, 32806
University of California Davis Comprehensive Cancer Center ( Site 0005)
Sacramento, California, 95817
Swedish Medical Center ( Site 0021)
Seattle, Washington, 98104
Sanford Cancer Center ( Site 0058)
Sioux Falls, South Dakota, 57104
Canada7 sites
BC Cancer - Abbotsford ( Site 0200)
Abbotsford British Columbia, British Columbia, V2S 0C2
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0208)
Hamilton, Ontario, L8V 4X2
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0210)
Montreal, Quebec, H2X 3E4
CHU de Quebec Universite de Laval ( Site 0206)
Québec, Quebec, G1R 2J6
Sunnybrook Research Institute ( Site 0207)
Toronto, Ontario, M4N 3M5
Princess Margaret Cancer Centre ( Site 0202)
Toronto, Ontario, M5G 2M9
CancerCare Manitoba ( Site 0201)
Winnipeg, Manitoba, R3E 0V9
Argentina6 sites
Hospital Aleman ( Site 2100)
Buenos Aires, Buenos Aires F.D., 1118
CEMIC ( Site 2104)
Buenos Aires, C1431FWO
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 2101)
Caba, C1012AAR
Fundacion Favaloro para la Docencia e Investigacion Medica ( Site 2106)
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1078AAI
Hospital Britanico de Buenos Aires ( Site 2109)
Ciudad de Buenos Aires, Buenos Aires F.D., C1280AEB
Instituto de Oncologia de Rosario ( Site 2105)
Rosario, Santa Fe Province, S2000KZE
France6 sites
Centre Oscar Lambret ( Site 0401)
Lille, Nord, 59000
Centre Leon Berard ( Site 0405)
Lyon, Auvergne, 69373
Centre Antoine Lacassagne ( Site 0404)
Nice, Alpes-Maritimes, 06189
Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0402)
Saint-Herblain, Val-de-Marne, 44805
Institut Claudius Regaud IUCT Oncopole ( Site 0403)
Toulouse, Haute-Garonne, 31059
Institut Gustave Roussy ( Site 0400)
Villejuif, Val-de-Marne, 94800
Germany6 sites
Universitaetsklinikum Frankfurt ( Site 0306)
Frankfurt am Main, Hesse, 60528
SRH Wald-Klinikum Gera GmbH ( Site 0309)
Gera, Thuringia, 07548
Universitaetsklinikum Jena ( Site 0302)
Jena, Thuringia, 07740
Universitaetsklinikum Regensburg ( Site 0304)
Regensburg, Bavaria, 93053
Robert Bosch GmbH ( Site 0307)
Stuttgart, Baden-Wurttemberg, 70376
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0301)
Wiesbaden, Hesse, 65199
Russia6 sites
Arkhangelsk Clinical Oncological Dispensary ( Site 1600)
Arkhangelsk, Arkhangelskaya oblast, 163045
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1603)
Kazan', Tatarstan, Respublika, 420029
Russian Oncological Research Center n.a. N.N. Blokhin ( Site 1604)
Moscow, Moscow, 115478
Leningrad Regional Oncology Center ( Site 1609)
Saint Petersburg, Sankt-Peterburg, 188663
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1610)
Saint Petersburg, Sankt-Peterburg, 197758
City Clinical Oncology Center ( Site 1608)
Saint Petersburg, Sankt-Peterburg, 198255
Switzerland6 sites
Ospedale Regionale di Bellinzona e Valli ( Site 1703)
Bellinzona, Canton Ticino, 6500
Inselspital Universitaetsspital Bern ( Site 1705)
Bern, Canton of Bern, 3010
Kantonsspital Graubuenden ( Site 1704)
Chur, Kanton Graubünden, 7000
Hopitaux Universitaires de Geneve HUG ( Site 1701)
Geneva, 1211
Kantonsspital St. Gallen ( Site 1702)
Sankt Gallen, Canton of St. Gallen, 9007
Universitaetsspital Zurich ( Site 1700)
Zurich, 8091
Israel5 sites
Soroka Medical Center ( Site 0601)
Beersheba, 8457108
Rambam Medical Center ( Site 0602)
Haifa, 3109601
Hadassah Ein Kerem Medical Center ( Site 0604)
Jerusalem, 9112001
Chaim Sheba Medical Center ( Site 0600)
Ramat Gan, 5262000
Sourasky Medical Center ( Site 0603)
Tel Aviv, 6423906
United Kingdom5 sites
Cambridge University Hospitals NHS Trust ( Site 0803)
Cambridge, Cambridgeshire, CB2 0QQ
Leicester Royal Infirmary. Univ. Hosp. of Leicester NHS Trust ( Site 0804)
Leicester, Leicestershire, LE1 5WW
Guy's Hospital ( Site 0806)
London, London, City of, SE1 9RT
Royal Marsden Hospital (Sutton) ( Site 0800)
London, Surrey, SM3 5PT
Christie NHS Foundation Trust ( Site 0805)
Manchester, M20 4BX
Chile4 sites
Fundacion Arturo Lopez Perez ( Site 1201)
Santiago, Region M. de Santiago, 7500921
Pontificia Universidad Catolica de Chile ( Site 1202)
Santiago, Region M. de Santiago, 8330024
Hospital Clinico Universidad de Chile ( Site 1200)
Santiago, Region M. de Santiago, 8380456
Centro Investigación del Cáncer James Lind ( Site 1203)
Temuco, Araucania, 4780000
Colombia4 sites
Instituto Nacional de Cancerologia E.S.E ( Site 1102)
Bogotá, Bogota D.C., 110321
Fundacion Valle del Lili ( Site 1101)
Cali, Valle del Cauca Department, 760032
Fundacion Colombiana de Cancerologia Clinica Vida ( Site 1105)
Medellín, Antioquia, 050030
Oncologos del Occidente S.A. ( Site 1106)
Pereira, Risaralda Department, 660001
Italy4 sites
Istituto Nazionale Tumori Fondazione Pascale ( Site 1400)
Naples, 80131
Fondazione Policlinico Universitario A. Gemelli ( Site 1403)
Roma, 00168
Istituto Clinico Humanitas Research Hospital ( Site 1402)
Rozzano, Milano
Policlinico Le Scotte - A.O. Senese ( Site 1401)
Siena, Tuscany, 53100
Spain4 sites
Hospital Clinic i Provincial ( Site 0703)
Barcelona, 08036
Hospital Universitario Gregorio Maranon ( Site 0701)
Madrid, 28009
Clinica Universitaria de Navarra ( Site 0704)
Madrid, 28027
Hospital Ramon y Cajal ( Site 0702)
Madrid, 28034
Australia3 sites
Royal Brisbane and Women s Hospital ( Site 0901)
Herston, Queensland, 4029
Alfred Health ( Site 0902)
Melbourne, Victoria, 3004
Sir Charles Gairdner Hospital ( Site 0903)
Nedlands, Western Australia, 6009
South Korea3 sites
Seoul National University Hospital ( Site 1000)
Seoul, 03080
Severance Hospital Yonsei University Health System ( Site 1001)
Seoul, 03722
Asan Medical Center ( Site 1002)
Songpagu, Seoul, 05505
Thailand3 sites
Chulalongkorn University ( Site 5001)
Bangkok, Bangkok, 10330
Ramathibodi Hospital. ( Site 5002)
Bangkok, Bangkok, 10400
Siriraj Hospital ( Site 5003)
Bangkok, Bangkok, 10700
Taiwan2 sites
National Cheng Kung University Hospital ( Site 3003)
Tainan, 704
National Taiwan University Hospital ( Site 3000)
Taipei, 10002
About this study
Official title: A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma
- Being tested
- Pembrolizumab, Lenvatinib
- Keywords
- programmed cell death 1 (PD-1, PD1), programmed cell death ligand 1 (PD-L1, PDL1), programmed cell death ligand 2 (PD-L2, PDL2), tyrosine kinase inhibitor (TKI), multiple TKI, Vascular Endothelial Growth Factor Receptor (VEFG), Fibroblast Growth Factor (FGF), Platelet-Derived Growth Factor (PDGF)
- Medical subject headings
- Triple Negative Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Glioblastoma, Biliary Tract Neoplasms, Pancreatic Neoplasms, Parkinson Disease 4, Autosomal Dominant Lewy Body
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PembrolizumabBiological
Also called MK-3475, Keytruda®
Administered as an IV infusion on Day 1 Q3W.
LenvatinibDrug
Also called MK-7902, E7080, LENVIMA™
Administered orally once a day during each 21-day cycle.
| Study group | Role | What they receive |
|---|---|---|
| Pembrolizumab + Lenvatinib (Arm 1) | Experimental | Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years). Receives: Biological: Pembrolizumab; Drug: Lenvatinib |
| Lenvatinib Monotherapy (Arm 2) | Experimental | Participants receive lenvatinib 24 mg via oral capsule QD, to be administered until progressive disease or unacceptable toxicity (up to at least 2 years). Receives: Drug: Lenvatinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment
ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 by investigator assessment was presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
Measured: Up to approximately 66 months
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR)
ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. For participants with GBM, response was assessed according to RANO criteria whereby ORR was defined as the percentage of participants who had a best overall response of either Complete response (CR): Disappearance of all target lesions or Partial response (PR): sum of products of diameters decreased by ≥50% from baseline value. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 or RANO by BICR was presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.
Measured: Up to approximately 66 months
Number of Participants With One or More Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.
Measured: Up to approximately 66 months
Number of Participants Who Discontinued From Study Treatment Due to an AE
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued from study treatment due to an AE is presented.
Measured: Up to approximately 62 months
Secondary outcomes (8)
Disease Control Rate (DCR) Per RECIST 1.1 by Investigator Assessment
DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD]). Disease Control rate per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
Measured: Up to approximately 66 months
Disease Control Rate (DCR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm]). The appearance of one or more new lesions is also considered PD.]). For participants with GBM, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters [SPD] decreased by ≥ 50% from baseline value and SD: SPD <50% decreased from baseline, but <25% increased from nadir) and clinical performance status with steroid dose information. The DCR as assessed by BICR is presented.
Measured: Up to approximately 66 months
Duration of Response (DOR) Per RECIST 1.1 by Investigator Assessment
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. Duration of response per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
Measured: Up to approximately 66 months
Duration of Response (DOR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. For participants with GBM, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information. DOR assessments were based on blinded central imaging review with confirmation.
Measured: Up to approximately 66 months
Progression-Free Survival (PFS) Per RECIST 1.1 by Investigator Assessment
PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who experienced PFS per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
Measured: Up to approximately 66 months
Progression-Free Survival (PFS) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1 (or RANO for GBM participants), modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. For participants with GBM, either radiological progression or clinical deterioration (not attributable to a nontumor-related cause) qualifies as PD. The percentage of participants who experienced PFS per RECIST 1.1 or RANO by BICR is presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.
Measured: Up to approximately 66 months
Overall Survival (OS)
OS was defined as the time from the date of study treatment to the date of death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. The OS for all participants is presented.
Measured: Up to approximately 66 months
Area Under the Concentration Curve at Steady State (AUCss) of Lenvatinib
Blood samples were collected at pre-specified timepoints to determine the AUCss in participants receiving Lenvatinib (Lenva) co-administered with Pembrolizumab (Pembro). AUCss was defined as a measure of drug exposure that was calculated as the product of plasma drug concentration and time after drug administration at steady state. AUCss determined by blood samples collected pre-dose and at designated timepoints post-dose are presented. Noncompartmental analysis was used to calculate AUC0ss for each participant. Mean and standard deviation of AUCss were calculated for each cohort. As specified in the protocol, pharmacokinetic analysis was not planned or conducted in Cohorts D2 and G.
Measured: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose and 2-12 hours post-dose; Cycle 2 Day 1: pre-dose, 0.5-4 hours, and 6-10 hours post-dose (up to approximately 23 days). Each cycle is 21 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2019
- Study start12 Feb 2019
- Primary completion28 Oct 2024
- Study completion28 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Advanced Solid TumorsStudies of the same condition, open and under way.
- More trials run by Merck Sharp & Dohme LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 611 participants (actual)
Sponsor and investigators
- Lead sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Eisai Inc.
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Merck Sharp & Dohme LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03797326
- Sponsor's protocol ID
- 7902-005
- Other IDs
- MK-7902-005, E7080-G000-224, LEAP-005, 2018-003747-37, 2018
- Status last verified
- Apr 2026
- First submitted
- 7 Jan 2019
- Last updated
- 4 May 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Publications
Gonzalez-Martin A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. 2024 Jul;186:182-190. doi: 10.1016/j.ygyno.2024.04.011. Epub 2024 May 7.
PubMed 38718741Chung HC, Saada-Bouzid E, Longo F, Yanez E, Im SA, Castanon E, Desautels DN, Graham DM, Garcia-Corbacho J, Lopez J, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Korakis I. Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study. Cancer. 2024 Oct 1;130(19):3278-3288. doi: 10.1002/cncr.35387. Epub 2024 Jun 21.
PubMed 39031824Ponz-Sarvise M, Rha SY, Gomez-Roca CA, Ortega Moran L, Gill S, Tortora G, Geva R, Saada-Bouzid E, Santoro A, Kim TW, Heudobler D, Dutcus CE, Okpara CE, Ghori R, Zhang Y, Vajdi A, Dettman EJ, Jin F, Groisberg R, Shapira-Frommer R. Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study. Cancer Res Commun. 2026 Mar 1;6(3):673-686. doi: 10.1158/2767-9764.CRC-26-0018.
PubMed 41747221Victoria Ruiz I, Uboha NV, Jamal R, Mejia FC, Ahumada M, Im SA, Gomez-Roca C, Shapira-Frommer R, Perets R, Yanez E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Castanon E. Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study. Clin Colorectal Cancer. 2026 Jun;25(2):225-238.e2. doi: 10.1016/j.clcc.2026.01.003. Epub 2026 Jan 22.
PubMed 41763955Rha SY, Castanon E, Gill S, Senellart H, Lopez J, Marquez-Rodas I, Victoria I, Kim TM, Lwin Z, Burger MC, Simonelli M, Cassier PA, Hendifar AE, Ascierto PA, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Villanueva L. Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort. Cancer. 2025 Aug 15;131(16):e70015. doi: 10.1002/cncr.70015.
PubMed 40808295
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)
- ClinicalTrials.gov ID
- NCT03797326
- Acronym / sponsor ID
- 7902-005
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma
- Keywords
- programmed cell death 1 (PD-1, PD1), programmed cell death ligand 1 (PD-L1, PDL1), programmed cell death ligand 2 (PD-L2, PDL2), tyrosine kinase inhibitor (TKI), multiple TKI, Vascular Endothelial Growth Factor Receptor (VEFG), Fibroblast Growth Factor (FGF), Platelet-Derived Growth Factor (PDGF)
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 611 participants (actual)
- Lead sponsor
- Merck Sharp & Dohme LLCIndustry (pharma, biotech, devices)
- Collaborators
- Eisai Inc.
- Study start
- 12 Feb 2019 (actual)
- Primary completion
- 28 Oct 2024 (actual)
- Study completion
- 28 Oct 2024 (actual)
- First posted
- 9 Jan 2019 (actual)
- Results
- Posted 17 Nov 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pembrolizumab + Lenvatinib (Arm 1) | Experimental | Biological: Pembrolizumab, Drug: LenvatinibParticipants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years). |
| Lenvatinib Monotherapy (Arm 2) | Experimental | Drug: LenvatinibParticipants receive lenvatinib 24 mg via oral capsule QD, to be administered until progressive disease or unacceptable toxicity (up to at least 2 years). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (31 listed)
- Has a histologically or cytologically-documented, advanced (metastatic and/or unresectable) solid tumor that is incurable and for which prior standard systemic therapy has failed in one of the following cohorts: TNBC, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, GBM, BTC (intrahepatic, extrahepatic cholangiocarcinoma and gall bladder cancer; excludes Ampulla of Vater), Pancreatic Cancer
- Must have progressed on or since the last treatment
- Has measurable disease per RECIST 1.1 (RANO for the GBM cohort) as assessed by the local site investigator/radiology and confirmed by BICR
- Has provided a PD-L1 evaluable archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
- Male participants agree to use approved contraception during the treatment period for at least 7 days after the last dose of lenvatinib, or refrain from heterosexual intercourse during this period
Key exclusion criteria (37 listed)
- Has gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib
- Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment (applies to all cohorts except the ovarian cancer cohort)
- Has radiographic evidence of encasement or invasion of a major blood vessel or of intratumoral cavitation. Participants with portal vein invasion (Vp4), inferior vena cava, or cardiac involvement based on imaging in the BTC cohort are not eligible for enrollment
- Has clinical significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study treatment
- Has significant cardiovascular impairment within 12 months of the first dose of study treatment, such as history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident (CVA), or cardiac arrhythmia associated with hemodynamic instability
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PembrolizumabAlso: MK-3475, Keytruda®Administered as an IV infusion on Day 1 Q3W. | Biological | Pembrolizumab + Lenvatinib (Arm 1) |
| LenvatinibAlso: MK-7902, E7080, LENVIMA™Administered orally once a day during each 21-day cycle. | Drug | Lenvatinib Monotherapy (Arm 2), Pembrolizumab + Lenvatinib (Arm 1) |
Primary outcome
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment
Time frame: Up to approximately 66 months
ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 by investigator assessment was presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR)
Time frame: Up to approximately 66 months
ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. For participants with GBM, response was assessed according to RANO criteria whereby ORR was defined as the percentage of participants who had a best overall response of either Complete response (CR): Disappearance of all target lesions or Partial response (PR): sum of products of diameters decreased by ≥50% from baseline value. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 or RANO by BICR was presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.
Number of Participants With One or More Adverse Events (AEs)
Time frame: Up to approximately 66 months
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.
Number of Participants Who Discontinued From Study Treatment Due to an AE
Time frame: Up to approximately 62 months
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued from study treatment due to an AE is presented.
8 secondary outcomes
Disease Control Rate (DCR) Per RECIST 1.1 by Investigator Assessment
Time frame: Up to approximately 66 months
Disease Control Rate (DCR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
Time frame: Up to approximately 66 months
Duration of Response (DOR) Per RECIST 1.1 by Investigator Assessment
Time frame: Up to approximately 66 months
Duration of Response (DOR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
Time frame: Up to approximately 66 months
Progression-Free Survival (PFS) Per RECIST 1.1 by Investigator Assessment
Time frame: Up to approximately 66 months
Progression-Free Survival (PFS) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
Time frame: Up to approximately 66 months
Overall Survival (OS)
Time frame: Up to approximately 66 months
Area Under the Concentration Curve at Steady State (AUCss) of Lenvatinib
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose and 2-12 hours post-dose; Cycle 2 Day 1: pre-dose, 0.5-4 hours, and 6-10 hours post-dose (up to approximately 23 days). Each cycle is 21 days.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 38718741Gonzalez-Martin A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. 2024 Jul;186:182-190. doi: 10.1016/j.ygyno.2024.04.011. Epub 2024 May 7.
- Results publication: PubMed 39031824Chung HC, Saada-Bouzid E, Longo F, Yanez E, Im SA, Castanon E, Desautels DN, Graham DM, Garcia-Corbacho J, Lopez J, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Korakis I. Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study. Cancer. 2024 Oct 1;130(19):3278-3288. doi: 10.1002/cncr.35387. Epub 2024 Jun 21.
- Results publication: PubMed 41747221Ponz-Sarvise M, Rha SY, Gomez-Roca CA, Ortega Moran L, Gill S, Tortora G, Geva R, Saada-Bouzid E, Santoro A, Kim TW, Heudobler D, Dutcus CE, Okpara CE, Ghori R, Zhang Y, Vajdi A, Dettman EJ, Jin F, Groisberg R, Shapira-Frommer R. Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study. Cancer Res Commun. 2026 Mar 1;6(3):673-686. doi: 10.1158/2767-9764.CRC-26-0018.
- Derived from this study: PubMed 41763955Victoria Ruiz I, Uboha NV, Jamal R, Mejia FC, Ahumada M, Im SA, Gomez-Roca C, Shapira-Frommer R, Perets R, Yanez E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Castanon E. Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study. Clin Colorectal Cancer. 2026 Jun;25(2):225-238.e2. doi: 10.1016/j.clcc.2026.01.003. Epub 2026 Jan 22.
- Derived from this study: PubMed 40808295Rha SY, Castanon E, Gill S, Senellart H, Lopez J, Marquez-Rodas I, Victoria I, Kim TM, Lwin Z, Burger MC, Simonelli M, Cassier PA, Hendifar AE, Ascierto PA, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Villanueva L. Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort. Cancer. 2025 Aug 15;131(16):e70015. doi: 10.1002/cncr.70015.
- Merck Clinical Trials InformationLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Related trials for Advanced Solid Tumors
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Merck Sharp & Dohme LLC
88 sites in 17 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Pembrolizumab and Lenvatinib in people with Advanced Solid Tumors and Triple Negative Breast Cancer, run by Merck Sharp & Dohme LLC at 88 sites in 17 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 31 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 88 sites in United States, Canada, Argentina, France, Germany and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Nov 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment (time frame: Up to approximately 66 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03797326, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.